Document Detail


Utilization of intravenous thrombolysis is increasing in the United States.
MedLine Citation:
PMID:  22882725     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Evaluating recombinant tissue plasminogen activator utilization rates is important, as many studies have demonstrated that administration of recombinant tissue plasminogen activator to qualified patients significantly improves prognosis. AIMS: We investigated recent trends in the utilization and outcomes of administration of intravenous recombinant tissue plasminogen activator in the United States using the National Inpatient Sample between 2001 and 2008. METHODS: We identified patients with a primary diagnosis of acute ischemic stroke who underwent treatment with intravenous recombinant tissue plasminogen activator and studied utilization rates and clinical outcomes: discharge to long-term facility (morbidity), in-hospital death (mortality), and intracranial hemorrhage. Information on demographics, hospital characteristics, and comorbidities was collected. A multivariate logistic regression analysis was performed to determine independent predictors of morbidity, mortality, and intracranial hemorrhage. RESULTS: Intravenous recombinant tissue plasminogen activator utilization increased from 1·3% in 2001 to 3·5% in 2008. On multivariate analysis, variables associated with increased morbidity after intravenous recombinant tissue plasminogen activator administration included advanced age (P < 0·001), female gender (P < 0·001), and comorbidities of atrial fibrillation (P < 0·001) and hypertension (P < 0·001). Increased mortality was associated with increased age (P < 0·001) and comorbidities of atrial fibrillation, congestive heart failure, coronary artery disease, and diabetes (P < 0·001 for all comorbidities). CONCLUSIONS: Intravenous recombinant tissue plasminogen activator utilization rates increased between 2001 and 2008. Advanced age and atrial fibrillation were significantly associated with increased morbidity and mortality among patients treated with intravenous recombinant tissue plasminogen activator.
Authors:
Deena M Nasr; Waleed Brinjikji; Harry J Cloft; Alejandro A Rabinstein
Related Documents :
1289175 - Sucralfate, ranitidine and no treatment in gastric ulcer management--a multicenter, pro...
17635595 - Efficacy and tolerability of naratriptan for short-term prevention of menstrually relat...
1742515 - A comparison of nizatidine and ranitidine in the maintenance treatment of duodenal ulce...
3891455 - Double-blind crossover study of the efficacy and acceptability of oxazepam expidet tabl...
18254805 - Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: c...
22953685 - Individualized quantified tricuspid valve annuloplasty for treating ebstein anomaly.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-9
Journal Detail:
Title:  International journal of stroke : official journal of the International Stroke Society     Volume:  -     ISSN:  1747-4949     ISO Abbreviation:  Int J Stroke     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101274068     Medline TA:  Int J Stroke     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization.
Affiliation:
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a ra...
Next Document:  Making death 'good': instructional tales for dying in newspaper accounts of Jade Goody's death.